Mesterolone
Error creating thumbnail: File missing | |
Clinical data | |
---|---|
ATC code | |
Identifiers | |
CAS Number | |
PubChem CID | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C20H32O2 |
Molar mass | 304.467 g/mol |
WikiDoc Resources for Mesterolone |
Articles |
---|
Most recent articles on Mesterolone Most cited articles on Mesterolone |
Media |
Powerpoint slides on Mesterolone |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Mesterolone at Clinical Trials.gov Clinical Trials on Mesterolone at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Mesterolone
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Mesterolone Discussion groups on Mesterolone Patient Handouts on Mesterolone Directions to Hospitals Treating Mesterolone Risk calculators and risk factors for Mesterolone
|
Healthcare Provider Resources |
Causes & Risk Factors for Mesterolone |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Mesterolone is an orally applicable androgen, and DHT derivative. It is sold under the brand name Proviron, by Schering. In the late 70's and early 80's it was used with some success in controlled studies of men suffering from various forms of depression.
In one randomized, double-blind 4-week trial, 38 dysthymic men were administered 75mg daily. Itil & Colleagues reported an improvement of symptoms which included anxiety, lack of drive and desire. Next, they administered a high dose (450mg/day) or placebo in a 6-week randomized trial of 52 men with a mean age of 40 years, suffering from dysthymia, unipolar and bipolar depression. Both the mesterolone and placebo groups improved significantly and there were no statistically significant differences between the two groups. In this series of studies mesterolone lead to a significant decrease in LH and testosterone levels. This is probably as a result of the extremely high dose used. In another, 100mg mesterolone cipionate was administered twice monthly. With regards to plasma T levels, there was no difference between the treated vs untreated group, and baseline LH levels were minimally affected.[1]
Mesterolone is a relatively weak androgen and rarely used for replacement therapies.[2]
References
- ↑ Archives of Dermatological Research (1977), Testosterone levels and gonadotrophins in klinefelter's patients treated with injections of mesterolone cipionate
- ↑ Human Reproduction Update (2004), Testosterone replacement therapy: current trends and future directions
- Frances Morrison, Mary. (2000) Hormones, Gender and the Aging Brain: The Endocrine Basis of Geriatric Psychiatry, Page 134, Cambridge University Press. ISBN 0521653045.
- Itil et al. The effects of mesterolone, a male sex hormone in depressed patients. 1984.
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs
- Androgens
- Anabolic steroids
- Endocrinology